First real-world validation of China’s YDHB-NS01 shows 100% success, shorter procedures than manual angiography, and no ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript March 12, 2026 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.22551.
A case study from Iceland shows how IoT pressure monitoring can support remote oversight of geothermal district heating infrastructure.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果